Amgen Acquires Dark Blue Therapeutics to Enhance Oncology Portfolio and Fight Aggressive Leukemias

Amgen Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics

Amgen has made a significant move in its commitment to oncology by acquiring Dark Blue Therapeutics, a biotech firm based in Oxford, England, for a total consideration of up to $840 million. This acquisition, which includes both upfront payments and milestone-related payments, aims to enhance Amgen's portfolio with Dark Blue's lead investigational molecule, DBT 3757. This therapy presents a first-in-class approach to treating Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), conditions that currently lack sufficient effective treatments. DBT 3757 is undergoing IND-enabling studies and has demonstrated promising anti-cancer activity in various leukemia models.

The scientific foundation of DBT 3757 is rooted in pioneering research from Oxford University, with initial funding from the LAB282 initiative. Dark Blue Therapeutics has garnered support from notable investors, including Bristol Myers Squibb and Evotec, underscoring the potential of its innovative therapeutic strategies. Alastair MacKinnon, CEO of Dark Blue, expresses confidence in Amgen’s capabilities to expedite the development of DBT 3757, especially for patients who do not respond to existing therapies. The acquisition reflects Amgen's intent to leverage its extensive experience in the development and commercialization of life-saving therapies, aiming to offer new options for patients battling these aggressive forms of cancer.

Jay Bradner, M.D., Amgen’s executive vice president of Research and Development, emphasizes the urgent need for novel mechanisms to combat AML, positioning the acquisition as a strategic enhancement to Amgen's ongoing research in targeted protein degradation and leukemia therapeutics. With this integration, Amgen not only bolsters its oncology pipeline but also reinforces its mission to deliver advanced healthcare solutions to underserved patient populations. This acquisition aligns with Amgen's broader strategy to invest in innovative biotech companies, further solidifying its role as a leader in the biotechnology sector and its commitment to address critical unmet medical needs.

In addition to this acquisition, Amgen continues to demonstrate its leadership in the biotech field, being recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers." The company is also set to present at the 2026 J.P. Morgan Healthcare Conference, showcasing its ongoing commitment to advancing healthcare solutions.

As Amgen integrates Dark Blue's innovative therapies, the biotechnology industry watches closely, anticipating advancements in treatment options for aggressive cancers that have long posed challenges for patients and healthcare providers alike.